Anti-inflammatory potential of Empagliflozin.
作者信息
Pirklbauer Markus
机构信息
Department of Internal Medicine IV-Nephrology and Hypertension, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria.
出版信息
Inflammopharmacology. 2021 Apr;29(2):573-576. doi: 10.1007/s10787-021-00797-9. Epub 2021 Mar 17.
Abstract
摘要
相似文献
1
Anti-inflammatory potential of Empagliflozin.恩格列净的抗炎潜力。
Inflammopharmacology. 2021 Apr;29(2):573-576. doi: 10.1007/s10787-021-00797-9. Epub 2021 Mar 17.
2
Apremilast, albiglutide, and empagliflozin.阿普斯特、阿必鲁肽和恩格列净。
J Am Pharm Assoc (2003). 2014 Sep-Oct;54(5):562-6. doi: 10.1331/JAPhA.2014.14533.
3
Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: Possible molecular pathways.钠-葡萄糖共转运蛋白 2 抑制剂与慢性肾脏病中的炎症：可能的分子途径。
J Cell Physiol. 2018 Jan;234(1):223-230. doi: 10.1002/jcp.26851. Epub 2018 Aug 4.
4
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂的降压及肾脏作用机制
Hypertension. 2020 Apr;75(4):894-901. doi: 10.1161/HYPERTENSIONAHA.119.11684. Epub 2020 Mar 2.
5
Empagliflozin protects heart from inflammation and energy depletion via AMPK activation.恩格列净通过激活 AMPK 保护心脏免受炎症和能量耗竭的影响。
Pharmacol Res. 2020 Aug;158:104870. doi: 10.1016/j.phrs.2020.104870. Epub 2020 May 17.
6
The SGLT2 Inhibitor Empagliflozin Might Be a New Approach for the Prevention of Acute Kidney Injury.恩格列净可能成为预防急性肾损伤的新方法。
Kidney Blood Press Res. 2019;44(2):149-157. doi: 10.1159/000498963. Epub 2019 Apr 2.
7
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration.1型糖尿病合并肾高滤过患者肾小球血流动力学对SGLT2抑制的反应特征
Diabetologia. 2014 Dec;57(12):2599-602. doi: 10.1007/s00125-014-3396-4. Epub 2014 Oct 4.
8
Metabolic Effects of Empagliflozin in Heart Failure: A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).恩格列净治疗心力衰竭的代谢效应：一项随机、双盲、安慰剂对照试验（Empire HF Metabolic）
Circulation. 2021 Jun;143(22):2208-2210. doi: 10.1161/CIRCULATIONAHA.120.053463. Epub 2021 Jun 1.
9
Empagliflozin, a sodium glucose co-transporter 2 inhibitor, in the treatment of type 1 diabetes.恩格列净，一种钠-葡萄糖共转运蛋白 2 抑制剂，在 1 型糖尿病治疗中的应用。
Expert Opin Investig Drugs. 2014 Jun;23(6):875-82. doi: 10.1517/13543784.2014.909407. Epub 2014 Apr 19.
10
[Empagliflozin in the elderly].[恩格列净用于老年人]
Geriatr Psychol Neuropsychiatr Vieil. 2021 Jun 1;19(2):137-147. doi: 10.1684/pnv.2021.0943.
引用本文的文献
1
Empagliflozin Mitigates PTZ-Induced Seizures in Rats: Modulating Npas4 and CREB-BDNF Signaling Pathway.恩格列净减轻大鼠戊四氮诱导的癫痫发作：调节Npas4和CREB-BDNF信号通路
J Neuroimmune Pharmacol. 2025 Jan 7;20(1):5. doi: 10.1007/s11481-024-10162-6.
2
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial.评估恩格列净对冠状动脉旁路移植术后预防心房颤动的效果：一项双盲、随机、安慰剂对照试验。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9935-9946. doi: 10.1007/s00210-024-03225-1. Epub 2024 Jul 2.
3
Emerging insights into the role of IL-1 inhibitors and colchicine for inflammation control in type 2 diabetes.对白细胞介素-1抑制剂和秋水仙碱在2型糖尿病炎症控制中作用的新见解。
Diabetol Metab Syndr. 2024 Jun 25;16(1):140. doi: 10.1186/s13098-024-01369-x.
4
Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review.炎症环境下，针对某些促炎细胞因子和途径的治疗策略可减轻缺血/再灌注引起的肝损伤：全面综述。
Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6299-6315. doi: 10.1007/s00210-024-03074-y. Epub 2024 Apr 21.
5
Potential use of sodium glucose co-transporter 2 inhibitors during acute illness: a systematic review based on COVID-19.钠-葡萄糖共转运蛋白 2 抑制剂在急性疾病期间的潜在用途：基于 COVID-19 的系统评价。
Endocrine. 2024 Aug;85(2):660-675. doi: 10.1007/s12020-024-03758-8. Epub 2024 Mar 6.
6
Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin-resistant canine model.达格列净可预防胰岛素抵抗犬模型的腹部内脏和皮下脂肪组织功能障碍。
Obesity (Silver Spring). 2023 Jul;31(7):1798-1811. doi: 10.1002/oby.23771. Epub 2023 May 23.
7
Gliflozins Have an Anti-Inflammatory Effect on Renal Proximal Tubular Epithelial Cells in a Diabetic and Inflammatory Microenvironment In Vitro.格列净类药物在体外糖尿病及炎症微环境中对肾近端小管上皮细胞具有抗炎作用。
Int J Mol Sci. 2023 Jan 17;24(3):1811. doi: 10.3390/ijms24031811.
8
Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.盐皮质激素受体拮抗剂在治疗2型糖尿病相关慢性肾脏病中的进展
Mayo Clin Proc Innov Qual Outcomes. 2022 Oct 15;6(6):536-551. doi: 10.1016/j.mayocpiqo.2022.09.002. eCollection 2022 Dec.
9
Empagliflozin Ameliorates Progression From Prediabetes to Diabetes and Improves Hepatic Lipid Metabolism: A Systematic Review.恩格列净改善糖尿病前期向糖尿病的进展并改善肝脏脂质代谢：一项系统评价。
Cureus. 2022 Aug 25;14(8):e28367. doi: 10.7759/cureus.28367. eCollection 2022 Aug.
10
Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein.恩格列净对表达人C反应蛋白的自发性高血压大鼠的有益作用是通过减轻肾脏炎症和氧化应激介导的。
Biomedicines. 2022 Aug 24;10(9):2066. doi: 10.3390/biomedicines10092066.
本文引用的文献
1
Empagliflozin Inhibits Basal and IL-1β-Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells.恩格列净抑制人近端肾小管细胞基础状态及白介素-1β介导的单核细胞趋化蛋白-1/CCL2 和内皮素-1 的表达。
Int J Mol Sci. 2020 Nov 1;21(21):8189. doi: 10.3390/ijms21218189.
2
Dapagliflozin in Patients with Chronic Kidney Disease.达格列净治疗慢性肾脏病患者。
N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24.
3
Empagliflozin suppresses inflammation and protects against acute septic renal injury.恩格列净可抑制炎症反应，防止急性脓毒症肾损伤。
Inflammopharmacology. 2021 Feb;29(1):269-279. doi: 10.1007/s10787-020-00732-4. Epub 2020 Jun 20.
4
The tubular hypothesis of nephron filtration and diabetic kidney disease.管状假说在肾单位滤过和糖尿病肾病中的作用。
Nat Rev Nephrol. 2020 Jun;16(6):317-336. doi: 10.1038/s41581-020-0256-y. Epub 2020 Mar 9.
5
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.钠-葡萄糖共转运蛋白 2 抑制剂：治疗糖尿病肾病的新靶点。
Nephrol Dial Transplant. 2020 Jan 1;35(Suppl 1):i13-i23. doi: 10.1093/ndt/gfz237.
6
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.恩格列净可减轻心力衰竭相关的 NLRP3（核苷酸结合寡聚化结构域样受体蛋白 3）炎症小体激活导致的心脏功能恶化。
Circ Heart Fail. 2020 Jan;13(1):e006277. doi: 10.1161/CIRCHEARTFAILURE.119.006277. Epub 2020 Jan 20.
7
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
8
Interleukin-1β Inhibition for Chronic Kidney Disease in Obese Mice With Type 2 Diabetes.白细胞介素-1β 抑制肥胖 2 型糖尿病小鼠的慢性肾脏病。
Front Immunol. 2019 May 29;10:1223. doi: 10.3389/fimmu.2019.01223. eCollection 2019.
9
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.卡格列净可降低炎症和纤维化生物标志物：SGLT2 抑制剂在糖尿病肾病中有益作用的潜在作用机制。
Diabetologia. 2019 Jul;62(7):1154-1166. doi: 10.1007/s00125-019-4859-4. Epub 2019 Apr 17.
10
Unraveling reno-protective effects of SGLT2 inhibition in human proximal tubular cells.解析 SGLT2 抑制在人近端肾小管细胞中的肾保护作用。
Am J Physiol Renal Physiol. 2019 Mar 1;316(3):F449-F462. doi: 10.1152/ajprenal.00431.2018. Epub 2018 Dec 12.
Zotero 插件